Diligence memo · auto-generated · as of July 3, 2026
Montlake Bioscience Inc.
Montlake Bioscience Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Montlake Bioscience Inc. operates in Biotech, based in LAS VEGAS.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Montlake Bioscience Inc. has raised $11M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $11M on 2018-10-19.
Most recent recorded round closed around 2018-10-19.
Valuation (modeled)modeled
Provath models Montlake Bioscience Inc. at approximately $410M (range $12M–$2.2B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.79× the median modeled value of Series A Biotech companies in 2016–2018 (8 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 7.7 yr ago; this sector typically re-raises about every 11 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 86% of Biotech peers (233 compared).
Modeled value ranks above 97% of those peers.
Closest niche peers: Impact Genomics, Inc., Transplant Genomics Inc., Benchling, Inc., Franklin BioScience - Penn LLC, Element Genomics, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.